Brief: Ideaya Biosciences Announces First-Patient-In For Phase 1 Trial Of IDE892
09/03/2026 11:03
March 9 (Reuters) - IDEAYA Biosciences Inc IDYA.O: IDEAYA BIOSCIENCES ANNOUNCES FIRST-PATIENT-IN FOR PHASE 1 TRIAL OF IDE892, A POTENTIAL BEST-IN-CLASS PRMT5 INHIBITOR FOR MTAP-DELETED SOLID TUMORS, AND PROVIDES MTAP AND CDKN2A PIPELINE UPDATE IDEAYA BIOSCIENCES INC - IDE892 TO BE COMBINED WITH IDE397 IN PHASE 1 TRIAL IN MID-2026 IDEAYA BIOSCIENCES INC - TARGETS CDKN2A DEVELOPMENT CANDIDATE NOMINATION IN H2 2026 AND IND IN H1 2027 Source text: ID:nPn2MrNyga Further company coverage: IDYA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on IDEAYA Biosciences
See all newsBrief: Ideaya Biosciences And Servier Announce Data From Three Clinical Trials At Esmo 2026 Supporting The Potential Of Darovasertib To Become A Foundational New Therapy For Patients Across The Treatment Journey Of Uveal Melanoma
Brief: Ideaya Biosciences Announces The Promotion Of Dr. Michael White To President, Research And Development
Brief: Ideaya Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Ideaya Biosciences Inc Reports Results For The Quarter Ended June 30: Earnings Summary
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj